flecainide has been researched along with Recrudescence in 54 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
| Excerpt | Relevance | Reference |
|---|---|---|
| "We tested the hypothesis that the response to flecainide infusion can identify patients with atrial fibrillation (AF) in whom the hybrid pharmacologic and ablation therapy reduces the recurrences of AF." | 9.09 | Response to flecainide infusion predicts long-term success of hybrid pharmacologic and ablation therapy in patients with atrial fibrillation. ( Astarita, C; De Matteis, C; De Simone, A; Di Napoli, T; La Rocca, V; Maresca, F; Nocerino, P; Stabile, E; Stabile, G; Turco, P; Vitale, DF, 2001) |
| "Aim of the present study was to assess the efficacy and safety of flecainide (F) and sotalol (S) for the prevention of recurrences of paroxysmal atrial fibrillation (PAF)." | 9.08 | [A comparison between flecainide and sotalol in the prevention of recurrences of paroxysmal atrial fibrillation]. ( Burattini, M; Carunchio, A; Ceci, V; Fera, MS; Galati, A; Greco, G; Mazza, A, 1995) |
| "The efficacy of oral cibenzoline (260 mg/day and 320 mg/day) and flecainide (200 mg/day and 300 mg/day) in the conversion of chronic atrial fibrillation to sinus rhythm were compared in 31 patients in a randomized order." | 9.07 | Randomized comparison of flecainide and cibenzoline in the conversion of atrial fibrillation. ( Kühlkamp, V; Risler, T; Schmid, F; Seipel, L, 1991) |
| "The efficacy and safety of flecainide were studied in the maintenance of sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter." | 9.06 | Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. ( Crijns, HJ; Hamer, HP; Lie, KI; Van Gelder, IC; Van Gilst, WH; Van Wijk, LM, 1989) |
| "The purpose of this study was to evaluate the hypothesis that presumed reversion of electrical remodeling after cardioversion of atrial fibrillation (AF) restores the efficacy of flecainide." | 7.73 | Does flecainide regain its antiarrhythmic activity after electrical cardioversion of persistent atrial fibrillation? ( Allessie, MA; Bennekers, JH; Bosker, HA; Bracke, FA; Crijns, HJ; Haaksma, J; Kingma, T; Kirchhof, CJ; Tieleman, RG; Van Gelder, IC; Veeger, NJ; Wilde, AA, 2005) |
| "Two infants with chaotic atrial tachycardia diagnosed at birth and at 11 weeks of life, were treated successfully with oral flecainide." | 7.68 | Successful treatment of chaotic atrial tachycardia with oral flecainide. ( Davignon, A; Fournier, A; Houyel, L, 1990) |
| "A 65-year-old man with paroxysmal atrial flutter was treated with digoxin and flecainide." | 7.68 | 1:1 atrioventricular conduction in atrial flutter with digoxin and flecainide. ( Ahsan, A; Aldridge, R; Bowes, R, 1993) |
| "The effect of flecainide acetate, a class 1c antiarrhythmic agent, was examined in 15 patients with recurrent ventricular tachycardia." | 7.67 | Effect of intravenous and oral flecainide on ventricular tachycardia. ( Cheesman, M; Dancy, M; Ward, DE, 1986) |
| "Oral flecainide was administered to 98 patients with arrhythmias regarded as resistant to other antiarrhythmic agents: quinidines (82), propafenone (40), beta-blockers (30), amiodarone alone (38) or combined with a class I compound (19)." | 7.67 | [Oral flecainide in the treatment of refractory arrhythmias. Long-term follow-up of 98 patients]. ( Benchimol, D; Blanchot, P; Haissaguerre, M; Le Métayer, P; Regaudie, JJ; Warin, JF, 1987) |
| "Four patients with recurrent, symptomatic ventricular tachycardia (VT) refractory to conventional antiarrhythmic agents were given flecainide acetate to control arrhythmias." | 7.66 | Clinical and electrophysiologic assessment of oral flecainide acetate for recurrent ventricular tachycardia: evidence for exacerbation of electrical instability. ( Abt, ME; Goldstein, RE; Oetgen, WJ; Tibbits, PA, 1983) |
| "Primary endpoint was symptomatic recurrence over 1-year follow-up." | 6.82 | Flecainide-metoprolol combination reduces atrial fibrillation clinical recurrences and improves tolerability at 1-year follow-up in persistent symptomatic atrial fibrillation. ( Capucci, A; Gabrielli, D; Guerra, F; Piangerelli, L; Ricciotti, J, 2016) |
| "Patients with paroxysmal atrial fibrillation (PAF) are prone to recurrence." | 6.67 | A randomized double-blind crossover study comparing the efficacy and tolerability of flecainide and quinidine in the control of patients with symptomatic paroxysmal atrial fibrillation. ( Lau, CP; Leung, WH; Wong, CK, 1992) |
| "Recurrence was noted to occur within 2 months of therapy." | 5.46 | Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy. ( Ermakov, S; Gerstenfeld, EP; Scheinman, MM; Svetlichnaya, Y, 2017) |
| "The flecainide infusion test has been proposed to screen candidates for hybrid pharmacological and ablation therapy." | 5.33 | Long-term results of hybrid therapy in patients with atrial fibrillation who develop atrial flutter during flecainide infusion. ( Astarita, C; De Matteis, C; De Simone, A; Di Napoli, T; El Jamal, B; Greco, L; La Rocca, V; Messina, V; Nocerino, P; Rotunno, R; Stabile, G; Turco, P; Vitale, DF, 2005) |
| "The management of patients with paroxysmal atrial fibrillation (AF) is unsuccessful, because AF recurs in about 50% of patients despite an antiarrhythmic treatment." | 5.30 | [The role of an electropharmacological transesophageal test in the prevention of paroxysmal atrial fibrillation. Experience with flecainide]. ( Accogli, S; Ciolli, A; De Sisti, A; Di Lorenzo, M; Lo Sardo, G; Matteucci, C; Palamara, A; Patrissi, T; Sasdelli, M, 1998) |
| "We tested the hypothesis that the response to flecainide infusion can identify patients with atrial fibrillation (AF) in whom the hybrid pharmacologic and ablation therapy reduces the recurrences of AF." | 5.09 | Response to flecainide infusion predicts long-term success of hybrid pharmacologic and ablation therapy in patients with atrial fibrillation. ( Astarita, C; De Matteis, C; De Simone, A; Di Napoli, T; La Rocca, V; Maresca, F; Nocerino, P; Stabile, E; Stabile, G; Turco, P; Vitale, DF, 2001) |
| "Aim of the present study was to assess the efficacy and safety of flecainide (F) and sotalol (S) for the prevention of recurrences of paroxysmal atrial fibrillation (PAF)." | 5.08 | [A comparison between flecainide and sotalol in the prevention of recurrences of paroxysmal atrial fibrillation]. ( Burattini, M; Carunchio, A; Ceci, V; Fera, MS; Galati, A; Greco, G; Mazza, A, 1995) |
| "The efficacy of oral cibenzoline (260 mg/day and 320 mg/day) and flecainide (200 mg/day and 300 mg/day) in the conversion of chronic atrial fibrillation to sinus rhythm were compared in 31 patients in a randomized order." | 5.07 | Randomized comparison of flecainide and cibenzoline in the conversion of atrial fibrillation. ( Kühlkamp, V; Risler, T; Schmid, F; Seipel, L, 1991) |
| "The relative safety and efficacy of intravenous administration of adenosine, lignocaine, disopyramide, flecainide, and sotalol for termination of stable, induced ventricular tachycardia was assessed in serial trials." | 5.06 | Relative efficacy and safety of intravenous drugs for termination of sustained ventricular tachycardia. ( Camm, AJ; Garratt, CJ; Griffith, MJ; Linker, NJ; Ward, DE, 1990) |
| "The efficacy and safety of flecainide were studied in the maintenance of sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter." | 5.06 | Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. ( Crijns, HJ; Hamer, HP; Lie, KI; Van Gelder, IC; Van Gilst, WH; Van Wijk, LM, 1989) |
| "Among the drugs recommended to prevent recurrences of atrial fibrillation after external electric shock, antiarrhythmic agents of classes Ia (quinidine, disopyramide), Ic (cibenzoline, flecainide, propafenone) and III (sotalol) seem to have the same effectiveness in maintaining the sinus rhythm in about 50 percent of the cases after 6 months and one year." | 4.78 | [Antiarrhythmic treatment after reduction of atrial fibrillation by external shock]. ( Brechenmacher, C; Chauvin, M; Koenig, A; Theolade, R, 1993) |
| " Herein, through data mining with supportive statistical analyses, we identified and consolidated variables of the Flecainide Short-Long (Flec-SL-AFNET 3) trial dataset that are associated with the primary outcome of the trial, recurrence of persistent atrial fibrillation (AF) or death." | 3.85 | Predictors of sinus rhythm after electrical cardioversion of atrial fibrillation: results from a data mining project on the Flec-SL trial data set. ( Borggrefe, M; Breithardt, G; Goette, A; Güvenir, HA; Karaagaoglu, E; Katircioglu-Öztürk, D; Kirchhof, P; Okutucu, S; Oto, A; Oto, E; Ravens, U; Steinbeck, G; Wegscheider, K, 2017) |
| "The purpose of this study was to evaluate the hypothesis that presumed reversion of electrical remodeling after cardioversion of atrial fibrillation (AF) restores the efficacy of flecainide." | 3.73 | Does flecainide regain its antiarrhythmic activity after electrical cardioversion of persistent atrial fibrillation? ( Allessie, MA; Bennekers, JH; Bosker, HA; Bracke, FA; Crijns, HJ; Haaksma, J; Kingma, T; Kirchhof, CJ; Tieleman, RG; Van Gelder, IC; Veeger, NJ; Wilde, AA, 2005) |
| "These findings demonstrate that, in Brugada syndrome, spontaneous or ajmaline-induced changes in the surface ECG may be paralleled by significant variations in the right ventricular endocardial electrogram that may result in ICD malfunction." | 3.70 | Spatial and temporal heterogeneity of depolarization and repolarization may complicate implantable cardioverter defibrillator therapy in Brugada syndrome. ( Bella, PD; Carbucicchio, C; Schmidinger, H; Stix, G, 2000) |
| "In order to determine the efficacy of type 1C agents (flecainide, encainide, propafenone) in patients with atrial fibrillation who have failed to maintain sinus rhythm with type 1A agents (quinidine, procainamide, disopyramide), 147 patients, that were admitted into the John Dempsey Hospital with new or recurrent atrial fibrillation between 1987-1991, were studied retrospectively." | 3.68 | Efficacy of type 1C antiarrhythmic agents for treatment of resistant atrial fibrillation. ( Grey, E; Silverman, DI, 1993) |
| "A 65-year-old man with paroxysmal atrial flutter was treated with digoxin and flecainide." | 3.68 | 1:1 atrioventricular conduction in atrial flutter with digoxin and flecainide. ( Ahsan, A; Aldridge, R; Bowes, R, 1993) |
| "Two infants with chaotic atrial tachycardia diagnosed at birth and at 11 weeks of life, were treated successfully with oral flecainide." | 3.68 | Successful treatment of chaotic atrial tachycardia with oral flecainide. ( Davignon, A; Fournier, A; Houyel, L, 1990) |
| "The effect of flecainide acetate, a class 1c antiarrhythmic agent, was examined in 15 patients with recurrent ventricular tachycardia." | 3.67 | Effect of intravenous and oral flecainide on ventricular tachycardia. ( Cheesman, M; Dancy, M; Ward, DE, 1986) |
| "A population of 50 patients suffering from paroxysmal attacks of atrial fibrillation was studied prospectively to evaluate the prognostic value of 20 variables: 6 clinical variables: sex, age, cardiopathy, number of arrhythmic attacks, "vagal" triggering, failure of class IA antiarrhythmic agents; 3 echocardiographic variables: left ventricular diastolic diameter and percentage of fibre shortening, left atrial diameter; 6 basic electrophysiological data: threshold, refractory periods at 110 and 150/min, modalities of induction of a sustained arrhythmia; 4 results observed with an infusion of flecainide in doses of 2 mg/kg: arrest or persistence of the arrhythmia, whether or not it could be reinduced and value of refractory periods; doses of flecainide administered orally." | 3.67 | [Predictive factors of the therapeutic result in the prevention of auricular fibrillation. Role of electrophysiological studies]. ( Commenges, D; Dulhoste, MN; Haissaguerre, M; Lemetayer, P; Salamon, R; Warin, JF, 1988) |
| "Oral flecainide was administered to 98 patients with arrhythmias regarded as resistant to other antiarrhythmic agents: quinidines (82), propafenone (40), beta-blockers (30), amiodarone alone (38) or combined with a class I compound (19)." | 3.67 | [Oral flecainide in the treatment of refractory arrhythmias. Long-term follow-up of 98 patients]. ( Benchimol, D; Blanchot, P; Haissaguerre, M; Le Métayer, P; Regaudie, JJ; Warin, JF, 1987) |
| "Four patients with recurrent, symptomatic ventricular tachycardia (VT) refractory to conventional antiarrhythmic agents were given flecainide acetate to control arrhythmias." | 3.66 | Clinical and electrophysiologic assessment of oral flecainide acetate for recurrent ventricular tachycardia: evidence for exacerbation of electrical instability. ( Abt, ME; Goldstein, RE; Oetgen, WJ; Tibbits, PA, 1983) |
| "Neonatal tachyarrhythmia was observed in 31." | 2.90 | Antenatal Therapy for Fetal Supraventricular Tachyarrhythmias: Multicenter Trial. ( Hagiwara, A; Hamasaki, T; Horigome, H; Ikeda, T; Inamura, N; Kato, H; Katsuragi, S; Kawataki, M; Maeno, Y; Miyoshi, T; Nii, M; Sago, H; Sakaguchi, H; Shimizu, W; Shiraishi, I; Taketazu, M; Ueda, K; Yamamoto, H; Yasukochi, S; Yoda, H, 2019) |
| "Primary endpoint was symptomatic recurrence over 1-year follow-up." | 2.82 | Flecainide-metoprolol combination reduces atrial fibrillation clinical recurrences and improves tolerability at 1-year follow-up in persistent symptomatic atrial fibrillation. ( Capucci, A; Gabrielli, D; Guerra, F; Piangerelli, L; Ricciotti, J, 2016) |
| " Despite careful precautions, serious proarrhythmias, the major limiting side effect of dofetilide, still occurred during long-term follow-up." | 2.73 | Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function. ( Bauman, JL; Kehoe, RF; Leal, S; Mykytsey, A; Razminia, M; Saleem, M; Wang, T; Zheutlin, T, 2007) |
| "In case of PAF recurrence pts withdrew from the study." | 2.68 | [Comparison of anti-arrhythmic therapy guided by the transesophageal electropharmacologic test and emperic therapy in the prophylaxis of atrial fibrillation recurrence]. ( Burattini, M; Carunchio, A; Ceci, V; Coletta, C; Fera, MS; Galati, A; Mazza, A, 1997) |
| "In the not-responders, the mean time to recurrence was 75 +/- 48 days in group C and 75 +/- 62 days in group F(NS)." | 2.68 | [Comparative study of cibenzoline and flecainide by oral route for preventing recurrence of paroxysmal atrial tachyarrhythmias]. ( Babuty, D; Brembilla-Perrot, B; Breuillac, JC; Fauchier, JP; Funck, F; Garnier, LF; Maison-Blanche, P; Medvedowsky, JL; Peraudeau, P; Rouesnel, P; Scheck, F, 1997) |
| "Seventeen patients had documented recurrence of atrial arrhythmia (9 in the cibenzoline group, 8 in the flecainide group) during the study." | 2.68 | Cibenzoline versus flecainide in the prevention of paroxysmal atrial arrhythmias: a double-blind randomized study. ( Babuty, D; D'Hautefeuille, B; Mycinsky, C; Peraudeau, P; Pruvost, P; Scheck, F, 1995) |
| "Patients with paroxysmal atrial fibrillation (PAF) are prone to recurrence." | 2.67 | A randomized double-blind crossover study comparing the efficacy and tolerability of flecainide and quinidine in the control of patients with symptomatic paroxysmal atrial fibrillation. ( Lau, CP; Leung, WH; Wong, CK, 1992) |
| "Atrial flutter is most often arising from a macroreentry circuit in the right atrium or around scar tissue in case or previous cardiothoracic surgery." | 2.43 | [Atrial flutter and fibrillation]. ( Scharf, C, 2005) |
| "With a probability of success of 90%, a recurrence rate of 5% to 15%, and few complications, catheter ablation emerges as the best treatment of recurrent, symptomatic flutter." | 2.41 | Management of atrial flutter. ( Aass, H; Kongsgaard, E, 2000) |
| "Recurrence was noted to occur within 2 months of therapy." | 1.46 | Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy. ( Ermakov, S; Gerstenfeld, EP; Scheinman, MM; Svetlichnaya, Y, 2017) |
| "The flecainide infusion test has been proposed to screen candidates for hybrid pharmacological and ablation therapy." | 1.33 | Long-term results of hybrid therapy in patients with atrial fibrillation who develop atrial flutter during flecainide infusion. ( Astarita, C; De Matteis, C; De Simone, A; Di Napoli, T; El Jamal, B; Greco, L; La Rocca, V; Messina, V; Nocerino, P; Rotunno, R; Stabile, G; Turco, P; Vitale, DF, 2005) |
| "Average follow up at first AF recurrence was 18." | 1.31 | Atrial fibrillation recurrence after internal cardioversion: prognostic importance of electrophysiological parameters. ( Bacchi Reggiani, L; Bartolotti, M; Biffi, M; Boriani, G; Branzi, A; Zannoli, R, 2002) |
| "The management of patients with paroxysmal atrial fibrillation (AF) is unsuccessful, because AF recurs in about 50% of patients despite an antiarrhythmic treatment." | 1.30 | [The role of an electropharmacological transesophageal test in the prevention of paroxysmal atrial fibrillation. Experience with flecainide]. ( Accogli, S; Ciolli, A; De Sisti, A; Di Lorenzo, M; Lo Sardo, G; Matteucci, C; Palamara, A; Patrissi, T; Sasdelli, M, 1998) |
| "Patient 1 had frequent episodes of paroxysmal atrial fibrillation resistant to Class IA drugs." | 1.30 | ST segment elevation in the right precordial leads induced with class IC antiarrhythmic drugs: insight into the mechanism of Brugada syndrome. ( Fujiki, A; Hayashi, H; Inoue, H; Mizumaki, K; Nagasawa, H; Usui, M, 1999) |
| " In this study, we prospectively investigated the effects of AFI ablation and continuation of drug therapy in patients with AF who developed AFI due to long-term administration of class IC antiarrhythmic drugs." | 1.30 | Radiofrequency ablation of atrial flutter due to administration of class IC antiarrhythmic drugs for atrial fibrillation. ( Jung, W; Lewalter, T; Lüderitz, B; Schumacher, B; Vahlhaus, C; Wolpert, C, 1999) |
| "Oral flecainide was effective in a small number of infants, with no adverse effects (95% CI 0% to 12%), and may now be preferred as the primary prophylactic agent." | 1.29 | Digoxin or flecainide for prophylaxis of supraventricular tachycardia in infants? ( Gardiner, HM; O'Sullivan, JJ; Wren, C, 1995) |
| "In 65% of the patients there was no recurrence during a follow-up period of 11 +/- 10 months." | 1.28 | Flecainide acetate in the treatment of supraventricular tachycardias: value of programmed electrical stimulation for long-term prognosis. ( Crijns, HJ; Lie, KI; van Gilst, WH; van Wijk, LM; Wesseling, H, 1989) |
| " Pharmacokinetic variables were calculated--median terminal half life 7." | 1.28 | Paediatric use of flecainide in supraventricular tachycardia: clinical efficacy and pharmacokinetics. ( Bhamra, R; Haga, P; Holt, DW; Johnston, A; Rowland, E; Shinebourne, EA; Till, JA; Ward, DE, 1989) |
| "Flecainide was administered to other patients during spontaneous episodes of tachyarrhythmias." | 1.27 | [Treatment of recurrent supraventricular tachyarrhythmias with flecainide or a flecainide and amiodarone combination]. ( Capestro, F; Ciampani, N; Costantini, C; Fratadocchi, GB; Mazzanti, M; Molini, E; Purcaro, A, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (16.67) | 18.7374 |
| 1990's | 22 (40.74) | 18.2507 |
| 2000's | 15 (27.78) | 29.6817 |
| 2010's | 7 (12.96) | 24.3611 |
| 2020's | 1 (1.85) | 2.80 |
| Authors | Studies |
|---|---|
| Miyoshi, T | 1 |
| Maeno, Y | 1 |
| Hamasaki, T | 1 |
| Inamura, N | 1 |
| Yasukochi, S | 1 |
| Kawataki, M | 1 |
| Horigome, H | 1 |
| Yoda, H | 1 |
| Taketazu, M | 1 |
| Nii, M | 1 |
| Hagiwara, A | 1 |
| Kato, H | 1 |
| Shimizu, W | 3 |
| Shiraishi, I | 1 |
| Sakaguchi, H | 1 |
| Ueda, K | 1 |
| Katsuragi, S | 1 |
| Yamamoto, H | 1 |
| Sago, H | 1 |
| Ikeda, T | 1 |
| Capponi, G | 1 |
| Belli, G | 1 |
| Giovannini, M | 1 |
| Remaschi, G | 1 |
| Brambilla, A | 1 |
| Vannuccini, F | 1 |
| Favilli, S | 1 |
| Porcedda, G | 1 |
| De Simone, L | 1 |
| Hayashi, M | 1 |
| Miyauchi, Y | 1 |
| Iwasaki, YK | 1 |
| Yodogawa, K | 1 |
| Tsuboi, I | 1 |
| Uetake, S | 1 |
| Hayashi, H | 2 |
| Takahashi, K | 1 |
| Kamakura, T | 1 |
| Wada, M | 1 |
| Nakajima, I | 1 |
| Ishibashi, K | 1 |
| Miyamoto, K | 1 |
| Okamura, H | 1 |
| Noda, T | 1 |
| Aiba, T | 1 |
| Takaki, H | 1 |
| Yasuda, S | 1 |
| Ogawa, H | 1 |
| Makiyama, T | 1 |
| Kimura, T | 1 |
| Kamakura, S | 1 |
| Kusano, K | 1 |
| Capucci, A | 1 |
| Piangerelli, L | 1 |
| Ricciotti, J | 1 |
| Gabrielli, D | 1 |
| Guerra, F | 1 |
| Oto, E | 1 |
| Okutucu, S | 1 |
| Katircioglu-Öztürk, D | 1 |
| Güvenir, HA | 1 |
| Karaagaoglu, E | 1 |
| Borggrefe, M | 1 |
| Breithardt, G | 1 |
| Goette, A | 1 |
| Ravens, U | 1 |
| Steinbeck, G | 1 |
| Wegscheider, K | 1 |
| Oto, A | 1 |
| Kirchhof, P | 1 |
| Ermakov, S | 1 |
| Gerstenfeld, EP | 1 |
| Svetlichnaya, Y | 1 |
| Scheinman, MM | 1 |
| Drewitz, I | 1 |
| Rostock, T | 1 |
| Hoffmann, B | 1 |
| Steven, D | 1 |
| Servatius, H | 1 |
| Meinertz, T | 2 |
| Willems, S | 1 |
| Siaplaouras, S | 1 |
| Jung, J | 1 |
| Buob, A | 1 |
| Heisel, A | 1 |
| Bertaglia, E | 1 |
| Bonso, A | 1 |
| Zoppo, F | 1 |
| Proclemer, A | 1 |
| Verlato, R | 1 |
| Corò, L | 1 |
| Mantovan, R | 1 |
| Themistoclakis, S | 1 |
| Raviele, A | 1 |
| Pascotto, P | 1 |
| Turco, P | 2 |
| De Simone, A | 2 |
| La Rocca, V | 2 |
| El Jamal, B | 1 |
| Nocerino, P | 2 |
| Astarita, C | 2 |
| De Matteis, C | 2 |
| Messina, V | 1 |
| Greco, L | 1 |
| Rotunno, R | 1 |
| Di Napoli, T | 2 |
| Vitale, DF | 2 |
| Stabile, G | 2 |
| Tieleman, RG | 1 |
| Van Gelder, IC | 3 |
| Bosker, HA | 1 |
| Kingma, T | 1 |
| Wilde, AA | 2 |
| Kirchhof, CJ | 1 |
| Bennekers, JH | 1 |
| Bracke, FA | 1 |
| Veeger, NJ | 1 |
| Haaksma, J | 1 |
| Allessie, MA | 1 |
| Crijns, HJ | 4 |
| Scharf, C | 1 |
| Janko, S | 1 |
| Hoffmann, E | 1 |
| Bökenkamp, R | 1 |
| Schalij, MJ | 1 |
| Blom, NA | 1 |
| Mykytsey, A | 1 |
| Bauman, JL | 1 |
| Razminia, M | 1 |
| Zheutlin, T | 1 |
| Wang, T | 1 |
| Saleem, M | 1 |
| Leal, S | 1 |
| Kehoe, RF | 1 |
| Oetgen, WJ | 1 |
| Tibbits, PA | 1 |
| Abt, ME | 1 |
| Goldstein, RE | 1 |
| Grey, E | 1 |
| Silverman, DI | 1 |
| O'Sullivan, JJ | 1 |
| Gardiner, HM | 1 |
| Wren, C | 1 |
| Carunchio, A | 2 |
| Fera, MS | 2 |
| Mazza, A | 2 |
| Burattini, M | 2 |
| Greco, G | 1 |
| Galati, A | 2 |
| Ceci, V | 2 |
| Babuty, D | 2 |
| D'Hautefeuille, B | 1 |
| Scheck, F | 2 |
| Mycinsky, C | 1 |
| Pruvost, P | 1 |
| Peraudeau, P | 2 |
| Kohl, T | 1 |
| Tercanli, S | 1 |
| Kececioglu, D | 1 |
| Holzgreve, W | 1 |
| Koenig, A | 1 |
| Theolade, R | 1 |
| Chauvin, M | 1 |
| Brechenmacher, C | 1 |
| Ahsan, A | 1 |
| Aldridge, R | 1 |
| Bowes, R | 1 |
| Dorian, P | 1 |
| Naccarelli, GV | 1 |
| Coumel, P | 3 |
| Hohnloser, SH | 1 |
| Maser, MJ | 1 |
| Maison-Blanche, P | 1 |
| Brembilla-Perrot, B | 1 |
| Fauchier, JP | 1 |
| Garnier, LF | 1 |
| Rouesnel, P | 1 |
| Breuillac, JC | 1 |
| Funck, F | 1 |
| Medvedowsky, JL | 1 |
| Leenhardt, A | 1 |
| Thomas, O | 1 |
| Coletta, C | 1 |
| Bellandi, F | 1 |
| Dabizzi, RP | 1 |
| Mugnaioni, G | 1 |
| Cantini, F | 1 |
| Palchetti, R | 1 |
| De Sisti, A | 1 |
| Matteucci, C | 1 |
| Patrissi, T | 1 |
| Accogli, S | 1 |
| Di Lorenzo, M | 1 |
| Sasdelli, M | 1 |
| Ciolli, A | 1 |
| Lo Sardo, G | 1 |
| Palamara, A | 1 |
| Schumacher, B | 1 |
| Jung, W | 1 |
| Lewalter, T | 1 |
| Vahlhaus, C | 1 |
| Wolpert, C | 1 |
| Lüderitz, B | 1 |
| Nabar, A | 1 |
| Rodriguez, LM | 1 |
| Timmermans, C | 1 |
| Smeets, JL | 1 |
| Wellens, HJ | 1 |
| Fujiki, A | 1 |
| Usui, M | 1 |
| Nagasawa, H | 1 |
| Mizumaki, K | 1 |
| Inoue, H | 1 |
| Stix, G | 1 |
| Bella, PD | 1 |
| Carbucicchio, C | 1 |
| Schmidinger, H | 1 |
| Kongsgaard, E | 1 |
| Aass, H | 1 |
| Maresca, F | 1 |
| Stabile, E | 1 |
| Price, JF | 1 |
| Kertesz, NJ | 1 |
| Snyder, CS | 1 |
| Friedman, RA | 1 |
| Fenrich, AL | 1 |
| Antonielli, E | 1 |
| Pizzuti, A | 1 |
| Pálinkás, A | 1 |
| Tanga, M | 1 |
| Gruber, N | 1 |
| Michelassi, C | 1 |
| Varga, A | 1 |
| Bonzano, A | 1 |
| Gandolfo, N | 1 |
| Halmai, L | 1 |
| Bassignana, A | 1 |
| Imran, MB | 1 |
| Delnevo, F | 1 |
| Csanády, M | 1 |
| Picano, E | 1 |
| Biffi, M | 1 |
| Boriani, G | 1 |
| Bartolotti, M | 1 |
| Bacchi Reggiani, L | 1 |
| Zannoli, R | 1 |
| Branzi, A | 1 |
| Lau, CP | 1 |
| Leung, WH | 1 |
| Wong, CK | 1 |
| Kühlkamp, V | 1 |
| Schmid, F | 1 |
| Risler, T | 1 |
| Seipel, L | 1 |
| Van Gilst, WH | 3 |
| Hillege, H | 1 |
| Gosselink, AM | 1 |
| Lie, KI | 3 |
| Denjoy, I | 1 |
| Lucet, V | 1 |
| Do Ngoc, D | 1 |
| Magnier, S | 1 |
| Casasoprana, A | 1 |
| Griffith, MJ | 1 |
| Linker, NJ | 1 |
| Garratt, CJ | 1 |
| Ward, DE | 3 |
| Camm, AJ | 1 |
| Houyel, L | 1 |
| Fournier, A | 1 |
| Davignon, A | 1 |
| van Wijk, LM | 2 |
| Wesseling, H | 1 |
| Till, JA | 1 |
| Shinebourne, EA | 1 |
| Rowland, E | 1 |
| Bhamra, R | 1 |
| Haga, P | 1 |
| Johnston, A | 1 |
| Holt, DW | 1 |
| Hamer, HP | 1 |
| Haissaguerre, M | 2 |
| Warin, JF | 2 |
| Benchimol, D | 1 |
| Le Métayer, P | 1 |
| Regaudie, JJ | 1 |
| Blanchot, P | 1 |
| Purcaro, A | 1 |
| Capestro, F | 1 |
| Ciampani, N | 1 |
| Fratadocchi, GB | 1 |
| Mazzanti, M | 1 |
| Costantini, C | 1 |
| Molini, E | 1 |
| Hoff, PI | 1 |
| Tronstad, A | 1 |
| Oie, B | 1 |
| Ohm, OJ | 1 |
| Dulhoste, MN | 1 |
| Commenges, D | 1 |
| Salamon, R | 1 |
| Lemetayer, P | 1 |
| Cheesman, M | 1 |
| Dancy, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Single Site, Interventional, Comparative Study to Evaluate the Safety and Efficacy of Ranolazine Plus Metoprolol Combination vs. FlecainidE pluS Metoprolol Combination in ATrial Fibrillation Recurrences[NCT03162120] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2018-09-01 | Withdrawn (stopped due to new study type, it will be re-organiZed as an Investigator Initiated Study (IIS)) | ||
| Pilot Randomized Trial With Flecainide in ARVC Patients[NCT03685149] | Phase 2 | 23 participants (Actual) | Interventional | 2019-07-31 | Completed | ||
| Home-based Videoplethysmographic Detection of Atrial Fibrillation[NCT04267133] | 256 participants (Actual) | Interventional | 2018-05-24 | Completed | |||
| Risk Factors That Contribute to the Maintenance of Sinus Rhythm: A Prospective Study to Create a Prediction Model for Atrial Fibrillation Patients to Maintain Sinus Rhythm.[NCT04655443] | 77 participants (Actual) | Observational | 2017-08-29 | Terminated (stopped due to due to COVID-19) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The outcome measure is the AUC of the curve obtained from the ROC analysis. The curve is a combination of specificity and sensitivity of detecting atrial fibrillation. The range of the curve is 0.5-1.0 where 0.5 would be random detection of atrial fibrillation and 1.0 would be perfect performance. (NCT04267133)
Timeframe: 2 weeks
| Intervention | probability (Number) |
|---|---|
| All Participants | 0.74 |
6 reviews available for flecainide and Recrudescence
| Article | Year |
|---|---|
[Current strategies in the treatment of atrial fibrillation].
Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Cardiac Pacing, Artificial; Catheter Ab | 2008 |
[Atrial flutter and fibrillation].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Anti-Arrhythmia | 2005 |
[Drug treatment of atrial fibrillation].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti | 2006 |
[Antiarrhythmic treatment after reduction of atrial fibrillation by external shock].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Disopyramide; El | 1993 |
[Pharmacological treatment of atrial fibrillation].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibril | 1997 |
Management of atrial flutter.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Flutter; Catheter Ablation; Electrophysiologic Techniques, C | 2000 |
15 trials available for flecainide and Recrudescence
| Article | Year |
|---|---|
Antenatal Therapy for Fetal Supraventricular Tachyarrhythmias: Multicenter Trial.
Topics: Administration, Oral; Adult; Anti-Arrhythmia Agents; Atrial Flutter; Cesarean Section; Digoxin; Fema | 2019 |
Three-month lower-dose flecainide after catheter ablation of atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Drug Administration Schedule; | 2014 |
Flecainide-metoprolol combination reduces atrial fibrillation clinical recurrences and improves tolerability at 1-year follow-up in persistent symptomatic atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Therapy, Combination; Electrocardiography; F | 2016 |
Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flut | 2007 |
[A comparison between flecainide and sotalol in the prevention of recurrences of paroxysmal atrial fibrillation].
Topics: Adult; Aged; Atrial Fibrillation; Female; Flecainide; Follow-Up Studies; Humans; Male; Middle Aged; | 1995 |
Cibenzoline versus flecainide in the prevention of paroxysmal atrial arrhythmias: a double-blind randomized study.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Drug Toleran | 1995 |
A randomized comparison of flecainide versus verapamil in paroxysmal supraventricular tachycardia. The Flecainide Multicenter Investigators Group.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Electrocardiography; Female; Flecainide; | 1996 |
[Comparative study of cibenzoline and flecainide by oral route for preventing recurrence of paroxysmal atrial tachyarrhythmias].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Flecainide; Humans | 1997 |
[Comparison of anti-arrhythmic therapy guided by the transesophageal electropharmacologic test and emperic therapy in the prophylaxis of atrial fibrillation recurrence].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Echocardiography, Transesophageal; Female; Flecainide; | 1997 |
Response to flecainide infusion predicts long-term success of hybrid pharmacologic and ablation therapy in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; Atria | 2001 |
Clinical value of left atrial appendage flow for prediction of long-term sinus rhythm maintenance in patients with nonvalvular atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Flow Velocity; Echocardiography, Doppler, P | 2002 |
A randomized double-blind crossover study comparing the efficacy and tolerability of flecainide and quinidine in the control of patients with symptomatic paroxysmal atrial fibrillation.
Topics: Adult; Aged; Atrial Fibrillation; Chi-Square Distribution; Double-Blind Method; Electrocardiography, | 1992 |
Randomized comparison of flecainide and cibenzoline in the conversion of atrial fibrillation.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Chi-Square Distribution; Female; Flecainid | 1991 |
Relative efficacy and safety of intravenous drugs for termination of sustained ventricular tachycardia.
Topics: Adenosine; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Clinical Trials as Topic; Disopyramid | 1990 |
Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutte | 1989 |
33 other studies available for flecainide and Recrudescence
| Article | Year |
|---|---|
Supraventricular tachycardias in the first year of life: what is the best pharmacological treatment? 24 years of experience in a single centre.
Topics: Action Potentials; Adrenergic beta-Antagonists; Age Factors; Anti-Arrhythmia Agents; Digoxin; Drug T | 2021 |
Significance of electrocardiogram recording in high intercostal spaces in patients with early repolarization syndrome.
Topics: Adult; Anti-Arrhythmia Agents; Brugada Syndrome; Electrocardiography; Electrophysiologic Techniques, | 2016 |
Predictors of sinus rhythm after electrical cardioversion of atrial fibrillation: results from a data mining project on the Flec-SL trial data set.
Topics: Action Potentials; Algorithms; Anti-Arrhythmia Agents; Area Under Curve; Atrial Fibrillation; Data M | 2017 |
Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy.
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dysplasia; Catheter Ablation; Combin | 2017 |
[Supraventricular extrasystole after cardioversion with amiodarone].
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Premature Complex | 2012 |
Incidence and management of early recurrent atrial fibrillation (ERAF) after transthoracic electrical cardioversion.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Flecainide; Humans; Inject | 2004 |
Different clinical courses and predictors of atrial fibrillation occurrence after transisthmic ablation in patients with preablation lone atrial flutter, coexistent atrial fibrillation, and drug induced atrial flutter.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Co | 2004 |
Long-term results of hybrid therapy in patients with atrial fibrillation who develop atrial flutter during flecainide infusion.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Combined Modality Th | 2005 |
Does flecainide regain its antiarrhythmic activity after electrical cardioversion of persistent atrial fibrillation?
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Female; Flecainide; Humans | 2005 |
Flecainide for recurrent malignant ventricular arrhythmias in two siblings with Andersen-Tawil syndrome.
Topics: Andersen Syndrome; Anti-Arrhythmia Agents; Child; Child, Preschool; Defibrillators, Implantable; Fem | 2007 |
Clinical and electrophysiologic assessment of oral flecainide acetate for recurrent ventricular tachycardia: evidence for exacerbation of electrical instability.
Topics: Administration, Oral; Adult; Anti-Arrhythmia Agents; Electrocardiography; Flecainide; Heart Ventricl | 1983 |
Efficacy of type 1C antiarrhythmic agents for treatment of resistant atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Disopyramide; Encainide; Female; Flecainide; Hear | 1993 |
Digoxin or flecainide for prophylaxis of supraventricular tachycardia in infants?
Topics: Anti-Arrhythmia Agents; Digoxin; Drug Administration Schedule; Flecainide; Humans; Infant; Infant, N | 1995 |
Direct fetal administration of adenosine for the termination of incessant supraventricular tachycardia.
Topics: Adenosine; Digoxin; Female; Fetal Death; Flecainide; Gestational Age; Heart Rate; Humans; Hydrops Fe | 1995 |
1:1 atrioventricular conduction in atrial flutter with digoxin and flecainide.
Topics: Aged; Amiodarone; Atrial Flutter; Atrioventricular Node; Digoxin; Drug Therapy, Combination; Electro | 1993 |
[Pharmacological cardioversion of isolated atrial fibrillation: recovery of atrial mechanical function and correlation with duration of arrhythmia].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Data Interpretation, Stat | 1997 |
[The role of an electropharmacological transesophageal test in the prevention of paroxysmal atrial fibrillation. Experience with flecainide].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Chi-Square Dis | 1998 |
Radiofrequency ablation of atrial flutter due to administration of class IC antiarrhythmic drugs for atrial fibrillation.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation | 1999 |
Radiofrequency ablation of "class IC atrial flutter" in patients with resistant atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cath | 1999 |
ST segment elevation in the right precordial leads induced with class IC antiarrhythmic drugs: insight into the mechanism of Brugada syndrome.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Flecainide; Follow-Up Studies; Hea | 1999 |
Spatial and temporal heterogeneity of depolarization and repolarization may complicate implantable cardioverter defibrillator therapy in Brugada syndrome.
Topics: Adrenergic beta-Agonists; Adult; Ajmaline; Anti-Arrhythmia Agents; Bundle-Branch Block; Cardiac Paci | 2000 |
Flecainide and sotalol: a new combination therapy for refractory supraventricular tachycardia in children <1 year of age.
Topics: Anti-Arrhythmia Agents; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Therapy, Com | 2002 |
Atrial fibrillation recurrence after internal cardioversion: prognostic importance of electrophysiological parameters.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Electro | 2002 |
Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter.
Topics: Actuarial Analysis; Aged; Amiodarone; Analysis of Variance; Atrial Fibrillation; Atrial Flutter; Chr | 1991 |
[Our experience with flecainide acetate in resistant arrhythmias in children. Apropos of 35 cases].
Topics: Adolescent; Child; Child, Preschool; Electrocardiography; Female; Flecainide; Humans; Infant; Infant | 1991 |
Successful treatment of chaotic atrial tachycardia with oral flecainide.
Topics: Administration, Oral; Electrocardiography; Flecainide; Heart Atria; Heart Failure; Humans; Infant; I | 1990 |
Flecainide acetate in the treatment of supraventricular tachycardias: value of programmed electrical stimulation for long-term prognosis.
Topics: Adult; Aged; Cardiac Pacing, Artificial; Electrophysiology; Flecainide; Follow-Up Studies; Humans; M | 1989 |
Paediatric use of flecainide in supraventricular tachycardia: clinical efficacy and pharmacokinetics.
Topics: Administration, Oral; Adolescent; Age Factors; Child; Child, Preschool; Female; Flecainide; Half-Lif | 1989 |
[Oral flecainide in the treatment of refractory arrhythmias. Long-term follow-up of 98 patients].
Topics: Adult; Aged; Arrhythmias, Cardiac; Electrocardiography; Exercise Test; Female; Flecainide; Heart Fun | 1987 |
[Treatment of recurrent supraventricular tachyarrhythmias with flecainide or a flecainide and amiodarone combination].
Topics: Administration, Oral; Adult; Aged; Amiodarone; Drug Therapy, Combination; Electrocardiography; Femal | 1987 |
Electrophysiologic and clinical effects of flecainide for recurrent paroxysmal supraventricular tachycardia.
Topics: Adolescent; Adult; Aged; Cardiac Pacing, Artificial; Electrophysiology; Female; Flecainide; Humans; | 1988 |
[Predictive factors of the therapeutic result in the prevention of auricular fibrillation. Role of electrophysiological studies].
Topics: Aged; Atrial Fibrillation; Electrophysiology; Evaluation Studies as Topic; Female; Flecainide; Human | 1988 |
Effect of intravenous and oral flecainide on ventricular tachycardia.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Coronary Dise | 1986 |